Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options

References

• Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand. 1963;59:369–382.
   PubMedGoogle Scholar
• Erqou S, Kaptoge S, Perry PL, et al.; Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423.
   PubMed Web of Science ®Google Scholar
• Rawther T, Tabet F. Biology, pathophysiology and current therapies that affect lipoprotein (a) levels. J Mol Cell Cardiol. 2019;131:1–11.
   PubMed Web of Science ®Google Scholar
• Julius U, Tselmin S, Schatz U, et al. Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors. Clin Res Cardiol Suppl. 2019;14(Suppl 1):45–50.
   PubMedGoogle Scholar
• Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol. 1998;32(7):2035–2042.
   PubMed Web of Science ®Google Scholar
• Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. 2014;103(1):76–84.
   PubMed Web of Science ®Google Scholar
• Krempler F, Kostner G, Bolzano K, et al. Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B. Biochim Biophys Acta. 1979;575(1):63–70.
   PubMedGoogle Scholar
• Reyes-Soffer G, Ginsberg HN, Ramakrishnan R. The metabolism of lipoprotein (a): an ever-evolving story. J Lipid Res. 2017;58(9):1756–1764.
   PubMed Web of Science ®Google Scholar
• Ma L, Chan DC, Ooi EMM, et al. Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration. Metabolism. 2019;96:8–11.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526–537.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Fazio S, Viney NJ, et al. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. J Clin Lipidol. 2018;12(5):1313–1323.
   PubMed Web of Science ®Google Scholar
• Cegla J, Neely RDG, France M, et al. HEART UK consensus statement on lipoprotein(a): a call to action. Atherosclerosis. 2019;291:62–70.
   PubMed Web of Science ®Google Scholar
• Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374–392.
   PubMed Web of Science ®Google Scholar
• Vuorio A, Watts GF, Schneider WJ, et al. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med. 2020;287(1):2–18.
   PubMedGoogle Scholar
• Tsimikas S. A test in context: Lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692–711.
   PubMed Web of Science ®Google Scholar
• Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63(19):1982–1989.
   PubMed Web of Science ®Google Scholar
• Sebestjen M, Zegura B, Guzic-Salobir B, et al. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia. Wien Klin Wochenschr. 2001;113(3-4):113–118.
   PubMed Web of Science ®Google Scholar
• Bartens W, Rader DJ, Talley G, et al. Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. Atherosclerosis. 1994;108(2):149–147.
   PubMed Web of Science ®Google Scholar
• Crawford DC, Peng Z, Cheng J-F, et al. LPA and PLG sequence variation and kringle IV-2 copy number in two populations. Hum Hered. 2008;66(4):199–209.
   PubMed Web of Science ®Google Scholar
• Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992;90(1):52–60.
   PubMed Web of Science ®Google Scholar
• Berthold HK, Gouni-Berthold I. Hyperlipoproteinemia(a): clinical significance and treatment options. Atheroscler Suppl. 2013;14(1):1–5.
   PubMed Web of Science ®Google Scholar
• Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol. 2004;24(12):2219–2226.
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al.; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–2528.
   PubMed Web of Science ®Google Scholar
• Chasman DI, Shiffman D, Zee RYL, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203(2):371–376.
   PubMed Web of Science ®Google Scholar
• Kathiresan S, Willer CJ, Peloso GM, et al. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet. 2009;41(1):56–65.
   PubMed Web of Science ®Google Scholar
• Ober C, Nord AS, Thompson EE, et al. Genome-wide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q. J Lipid Res. 2009;50(5):798–806.
   PubMed Web of Science ®Google Scholar
• Lee S-R, Prasad A, Choi Y-S, et al. LPA gene, ethnicity, and cardiovascular events. Circulation. 2017;135(3):251–263.
   PubMed Web of Science ®Google Scholar
• Saleheen D, Haycock PC, Zhao W, et al. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes Endocrinol. 2017;5(7):524–533.
   PubMed Web of Science ®Google Scholar
• Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol. 1992;136(4):441–449.
   PubMed Web of Science ®Google Scholar
• Sandholzer C, Saha N, Kark JD, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb. 1992;12(10):1214–1226.
   PubMedGoogle Scholar
• Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation. 1993;87(4):1135–1141.
   PubMed Web of Science ®Google Scholar
• Singla S, Kaur K, Kaur G, et al. Lipoprotein (a) in type 2 diabetes mellitus: relation to LDL: HDL ratio and glycemic control. Int J Diab Dev Ctries. 2009;29(2):80–84.
   PubMed Web of Science ®Google Scholar
• Allen S, Khan S, Tam S. p, et al. Expression of adhesion molecules by lp(a): a potential novel mechanism for its atherogenicity. Faseb J. 1998;12(15):1765–1776.
   PubMed Web of Science ®Google Scholar
• Ornek E, Murat S, Duran M, et al. The relationship between lipoprotein(a) and coronary artery disease, as well as its variable nature following myocardial infarction. Clin Invest Med. 2011;34(1):E14–20.
   PubMed Web of Science ®Google Scholar
• Argraves KM, Kozarsky KF, Fallon JT, et al. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 1997;100(9):2170–2181.
   PubMed Web of Science ®Google Scholar
• Wu HD, Berglund L, Dimayuga C, et al. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol. 2004;43(10):1828–1833.
   PubMed Web of Science ®Google Scholar
• Scipione CA, Sayegh SE, Romagnuolo R, et al. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res. 2015;56(12):2273–2285.
   PubMed Web of Science ®Google Scholar
• Wang J, Hu B, Kong L, et al. Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin Chim Acta. 2008;390(1-2):67–71.
   PubMed Web of Science ®Google Scholar
• Borba EF, Santos RD, Bonfa E, et al. Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol. 1994;21(2):220–223.
   PubMed Web of Science ®Google Scholar
• Enkhmaa B, Anuurad E, Zhang W, et al. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol. 2013;33(2):387–392.
   PubMed Web of Science ®Google Scholar
• Qi Q, Qi L. Lipoprotein(a) and cardiovascular disease in diabetic patients. Clin Lipidol. 2012;7(4):397–407.
   PubMed Web of Science ®Google Scholar
• Qi Q, Workalemahu T, Zhang C, et al. Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J. 2012;33(3):325–334.
   PubMed Web of Science ®Google Scholar
• Ramharack R, Barkalow D, Spahr MA. Dominant negative effect of TGF-beta1 and TNF-alpha on basal and IL-6-induced lipoprotein(a) and apolipoprotein(a) mRNA expression in primary monkey hepatocyte cultures. Arterioscler Thromb Vasc Biol. 1998;18(6):984–990.
   PubMed Web of Science ®Google Scholar
• Riches K, Porter KE. Lipoprotein(a): cellular effects and molecular mechanisms. Cholesterol. 2012;2012:923289.
   PubMedGoogle Scholar
• Tada H, Takamura M, Kawashiri M-A. Lipoprotein(a) as an old and new causal risk factor of atherosclerotic cardiovascular disease. J Atheroscler Thromb. 2019;26(7):583–591.
   PubMed Web of Science ®Google Scholar
• Hajjar KA, Gavish D, Breslow JL, et al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 1989;339(6222):303–305.
   PubMed Web of Science ®Google Scholar
• Ellis KL, Boffa MB, Sahebkar A, et al. The renaissance of lipoprotein(a): Brave new world for preventive cardiology? Prog Lipid Res. 2017;68:57–82.
   PubMed Web of Science ®Google Scholar
• Sangrar W, Bajzar L, Nesheim ME, et al. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry. 1995;34(15):5151–5157.
   PubMed Web of Science ®Google Scholar
• Xue S, Madison EL, Miles LA. The Kringle V-protease domain is a fibrinogen binding region within Apo(a). Thromb Haemost. 2001;86(5):1229–1237.
   PubMed Web of Science ®Google Scholar
• Kang C, Dominguez M, Loyau S, et al. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol. 2002;22(7):1232–1238.
   PubMed Web of Science ®Google Scholar
• Tsironis LD, Mitsios JV, Milionis HJ, et al. Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res. 2004;63(1):130–138.
   PubMed Web of Science ®Google Scholar
• Green D, Foiles N, Chan C, et al. Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis. 2009;202(2):623–631.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen city heart study. Circulation. 2008;117(2):176–184.
   PubMed Web of Science ®Google Scholar
• Borén J, Chapman MJ, Krauss RM, Packard CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2020:ehz962.
   PubMed Web of Science ®Google Scholar
• Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635–642.
   PubMed Web of Science ®Google Scholar
• Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J. 2019;40(33):2760–2770.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–2339.
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470–477.
   PubMed Web of Science ®Google Scholar
• Kostner GM, Avogaro P, Cazzolato GME, et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38(1-2):51–61.
   PubMed Web of Science ®Google Scholar
• Madsen CM, Kamstrup PR, Langsted A, et al. Lipoprotein(a)-lowering by 50 mg/dL (105 nmol/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study. ATVB. 2020;40(1):255–266.
   Google Scholar
• Gencer B, Kronenberg F, Stroes ES, et al. Lipoprotein(a): the revenant. Eur Heart J. 2017;38(20):1553–1560.
   PubMed Web of Science ®Google Scholar
• Anderson TJ, Grégoire J, Pearson GJ, et al. Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32(11):1263–1282.
   PubMed Web of Science ®Google Scholar
• Ellis KL, Chakraborty A, Moses EK, et al. To test, or not to test: that is the question for the future of lipoprotein(a). Expert Rev Cardiovasc Ther. 2019;17(4):241–250.
   PubMed Web of Science ®Google Scholar
• Burgess S, Ference BA, Staley JR, et al.; European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. JAMA Cardiol. 2018;3(7):619–627.
   PubMed Web of Science ®Google Scholar
• Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503–512.
   PubMed Web of Science ®Google Scholar
• Cao J, Steffen BT, Budoff M, et al. Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in white and black individuals: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36(5):1003–1009.
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation. 2011;124(16):1783–1791.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Simental-Mendía LE, Watts GF, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) group. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med. 2017;15(1):22.
   PubMedGoogle Scholar
• Parish S, Hopewell JC, Hill MR, et al. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study. Circ Genomic Precis Med. 2018;11(2):e001696.
   PubMed Web of Science ®Google Scholar
• Landray MJ, Haynes R, Hopewell JC, et al. HPS2-THRIVE collaborative group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–212.
   PubMed Web of Science ®Google Scholar
• Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol. 2013;62(17):1575–1579.
   PubMed Web of Science ®Google Scholar
• The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2267.
   PubMed Web of Science ®Google Scholar
• Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation. 2013;128(24):2567–2576.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Gordts P, Nora C, et al. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2019;ehz310.
   Google Scholar
• Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet Lond Engl. 2018;392(10155):1311–1320.
   PubMed Web of Science ®Google Scholar
• Awad K, Mikhailidis DP, Katsiki N, et al.; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. On behalf of Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) group. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Drugs. 2018;78(4):453–462.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107.
   PubMed Web of Science ®Google Scholar
• Bittner VA, Szarek M, Aylward PE, et al.; ODYSSEY OUTCOMES Committees and Investigators. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75(2):133–144.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: Insights from the FOURIER trial. Circulation. 2019;139(12):1483–1492.
   PubMed Web of Science ®Google Scholar
• Shiffman D, Chasman DI, Ballantyne CM, et al. Coronary heart disease risk, aspirin use, and apolipoprotein(a) 4399Met allele in the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 2009;102(1):179–180.
   PubMed Web of Science ®Google Scholar
• Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem. 2002;48(9):1454–1459.
   PubMed Web of Science ®Google Scholar
• Shlipak MG. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283(14):1845.
   PubMed Web of Science ®Google Scholar
• van Wissen S, Smilde TJ, Trip MD, et al. Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia. Heart Br Card Soc. 2003;89(8):893–896.
   PubMedGoogle Scholar
• Yeang C, Hung M-Y, Byun Y-S, et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol. 2016;10(3):594–603.
   PubMed Web of Science ®Google Scholar
• Takagi H, Umemoto T. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int J Cardiol. 2012;154(2):183–186.
   PubMed Web of Science ®Google Scholar
• Rader DJ, Kastelein J. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129(9):1022–1032.
   PubMed Web of Science ®Google Scholar
• van Capelleveen JC, van der Valk FM, Stroes E. Current therapies for lowering lipoprotein (a). J Lipid Res. 2016;57(9):1612–1618.
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Wierzbicki AS, et al. Lipoprotein a: where are we now? Curr Opin Cardiol. 2009;24(4):351–357.
   PubMed Web of Science ®Google Scholar
• Chennamsetty I, Kostner KM, Claudel T, et al. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. J Lipid Res. 2012;53(11):2405–2412.
   PubMed Web of Science ®Google Scholar
• Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med. 1989;226(4):271–276.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Reiner Ž, Simental-Mendía LE, et al. Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism. 2016;65(11):1664–1678.
   PubMed Web of Science ®Google Scholar
• Cao Y-X, Liu H-H, Li S, et al. A meta-analysis of the effect of PCSK9-monoclonal antibodies on circulating lipoprotein (a) Levels. Am J Cardiovasc Drugs. 2019;19(1):87–97.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;114(5):711–715.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145). J Am Coll Cardiol. 2014;63(13):1278–1288.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. The Lancet. 2015;386(10002):1472–1483.
   PubMed Web of Science ®Google Scholar
• Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet. 2016;388(10057):2239–2253.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382(3):244–255.
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. The Lancet. 2010;375(9719):998–1006.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Alexander VJ, Baker BF, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438–447.
   PubMed Web of Science ®Google Scholar
• Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430–1440.
   PubMed Web of Science ®Google Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519.
   PubMed Web of Science ®Google Scholar
• Thompson G, Parhofer KG. Current role of lipoprotein apheresis. Curr Atheroscler Rep. 2019;21(7):26.
   PubMed Web of Science ®Google Scholar
• Schettler VJJ, Neumann CL, Peter C, Scientific Board of GLAR for, et al. the German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on. Clin Res Cardiol Suppl. 2017;12(Suppl 1):44–49.
   PubMedGoogle Scholar
• Ranga GS, Kalra OP, Tandon H, et al. Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2007;16(5):220–224.
   PubMedGoogle Scholar
• McNeil JJ, Nelson MR, Woods RL, et al.; ASPREE Investigator Group. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–1528.
   PubMed Web of Science ®Google Scholar
• The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–1539.
   PubMed Web of Science ®Google Scholar
• Costello BT, Silverman ER, Doukky R, et al. Lipoprotein(a) and increased cardiovascular risk in women. Clin Cardiol. 2016;39(2):96–102.
   PubMed Web of Science ®Google Scholar
• Porkka KV, Erkkola R, Taimela S, et al. Influence of oral contraceptive use on lipoprotein (a) and other coronary heart disease risk factors. Ann Med. 1995;27(2):193–198.
   PubMed Web of Science ®Google Scholar
• Suk Danik J, Rifai N, Buring JE, et al. Lipoprotein(a), hormone replacement therapy and risk of future cardiovascular events. J Am Coll Cardiol. 2008;52(2):124–131.
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann Intern Med. 2014;161(4):249–260.
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–1231.
   PubMed Web of Science ®Google Scholar